Adhesive patch biotech Zosano Pharma sets terms for $70 million IPO

By
A A A

Zosano Pharma, a biotech developing a transdermal delivery system to treat osteoporosis, announced terms for its IPO on Wednesday. The Fremont, CA-based company plans to raise $70 million by offering 6.4 million shares at a price range of $10 to $12. At the midpoint of the proposed range, it would command a fully diluted market value of $139 million.

Zosano Pharma, which was spun out of Johnson & Johnson ( JNJ ) in 2006 and booked $3 million in license fee revenue for the 12 months ended March 31, 2014, plans to list on the NASDAQ under the symbol ZSAN. Wedbush PacGrow, Ladenburg Thalmann and Roth Capital are the joint bookrunners on the deal. No pricing date was disclosed.




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.




This article appears in: News Headlines , IPOs

Referenced Stocks: JNJ , ZSAN

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Freshman Finance 101
Freshman Finance 101                
Spot the Dropout RRC
Spot the Dropout RRC                
Power on/Power Off
Power on/Power Off                  

Stocks

Referenced

Most Active by Volume

63,683,265
  • $16.34 ▼ 0.12%
57,325,180
  • $10.64 ▲ 1.33%
54,257,396
  • $112.76 ▼ 0.47%
40,860,148
  • $5.86 ▲ 1.38%
40,102,780
  • $28.54 ▲ 0.42%
36,273,767
  • $104.31 ▼ 1.24%
36,196,207
  • $13.87 ▲ 0.95%
35,675,931
  • $10.40 ▲ 0.97%
As of 8/31/2015, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com